Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema

Ophthalmology

Volumn 117, Issue 6, 2010, Pages

  Elman, Michael J ^a   Aiello, Lloyd Paul ^a   Beck, Roy W ^a   Bressler, Neil M ^a   Bressler, Susan B ^a   Edwards, Allison R ^a   Ferris III, Frederick L ^a   Friedman, Scott M ^a   Glassman, Adam R ^a   Miller, Kellee M ^a   Scott, Ingrid U ^a   Stockdale, Cynthia R ^a   Sun, Jennifer K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; TRIAMCINOLONE;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CATARACT EXTRACTION; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ENDOPHTHALMITIS; EYE DISEASE; FEMALE; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR VASCULAR DISEASE; PRIORITY JOURNAL; PSEUDOENDOPHTHALMITIS; PSEUDOPHAKIA; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETREATMENT; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VASCULAR DEATH; VISUAL ACUITY; VITREOUS HEMORRHAGE;

EID: 77952779304     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.02.031     Document Type: Article

References (26)

1. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV: Diabetic macular edema. Ophthalmology 91 (1984) 1464-1474
2. Moss S.E., Klein R., and Klein B.E. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105 (1998) 998-1003
3. Moss S.E., Klein R., and Klein B.E. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 101 (1994) 1061-1070
4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985) 1796-1806
5. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115 (2008) 1447-1459
6. Aiello L.P., Avery R.L., Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331 (1994) 1480-1487
7. Antonetti D.A., Barber A.J., Hollinger L.A., et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopaty and tumors. J Bio Chem 274 (1999) 23463-23467
8. Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113 (2006) 23-28
9. Nguyen Q.D., Shah S.M., Heier J.S., et al., READ-2 Study Group. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. Ophthalmology 116 (2009) 2175-2181
10. Kang S.W., Sa H.S., Cho H.Y., and Kim J.I. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol 124 (2006) 653-658
11. Beck R.W., Moke P.S., Turpin A.H., et al. A computerized method of visual acuity testing: adaptation of the Early Treatment of Diabetic Retinopathy Study testing protocol. Am J Ophthalmol 135 (2003) 194-205
12. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114 (2007) 525-536
13. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Ophthalmology 98 suppl (1991) 823-833
14. Little R.J., Rubin D.B., and Barnett V. Statistical analysis with missing data. Wiley Series in Probability and Mathematical Statistics (1987), Wiley, New York 255-259
15. Moradian S., Ahmadieh H., Malihi M., et al. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246 (2008) 1699-1705
16. Arevalo J.F., Maia M., Flynn Jr. H.W., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 92 (2008) 213-216
17. ClinicalTrials.gov. Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy (LRTforDME+PRP). NCT00445003. Available at: http://public.drcr.net/Studies.aspx?ReclD5147. Accessed January 5, 2010.
18. Sabet-Peyman E.J., Heussen F.M., Thorne J.E., et al. Progression of macular ischemia following intravitreal bevacizumab. Ophthalmic Surg Lasers Imaging 40 (2009) 316-318
19. Ockrim Z.K., Sivaprasad S., Falk S., et al. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. Br J Ophthalmol 92 (2008) 795-799
20. Gillies M.C., Sutter F.K., Simpson J.M., et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113 (2006) 1533-1538
21. Martidis A., Duker J.S., Greenberg P.B., et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109 (2002) 920-927
22. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114 (2007) 1860-1867
23. ClinicalTrials.gov. Efficacy and safety of ranibizumab (intravitreal injections) in patients with visual impairment due to diabetic macular edema (RESTORE). NCT00687804. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00687804?term=nct00687804. Accessed January 5, 2010.
24. ClinicalTrials.gov. A study of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RIDE). NCT00473382. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00473382?term=NCT00473382. Accessed January 5, 2010.
25. ClinicalTrials.gov. A study of ranibizumab injection in subjects with clinically significant macular edema with center involvement secondary to diabetes mellitus (RISE). NCT00473330. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00473330. Accessed January 5, 2010.
26. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Fong D.S., Strauber S.F., Aiello L.P., et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 125 (2007) 469-480